Literature DB >> 19998015

Bortezomib induces erythema multiforme-like cutaneous adverse effects: report of two cases.

Peter Arne Gerber, Edwin Bölke, Bettina Alexandra Buhren, Daniela Bruch-Gerharz, Roland Fenk, Julia Reifenberger, Wilfried Budach, Rainer Haas, Bernhard Homey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19998015     DOI： 10.1007/s00508-009-1267-7

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  9 in total

Review 1.  Bortezomib-associated cutaneous vasculitis.

Authors:  X Garcia-Navarro; L Puig; M T Fernández-Figueras; J Dalmau; E Roe; A Alomar
Journal:  Br J Dermatol       Date:  2007-07-16       Impact factor: 9.302

2.  Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael Schuster; David Irwin; Edward Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Melissa Alsina; S Vincent Rajkumar; Martha Lacy; Andrzej Jakubowiak; William Dalton; Anthony Boral; Dixie-Lee Esseltine; David Schenkein; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-09       Impact factor: 22.113

3.  Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions.

Authors:  H Kokuba; L Aurelian; J Burnett
Journal:  J Invest Dermatol       Date:  1999-11       Impact factor: 8.551

4.  Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

Authors:  John Gerecitano; Andre Goy; John Wright; Barbara MacGregor-Cortelli; Ellen Neylon; Mithat Gonen; Dixie Esseltine; Anthony Boral; David Schenkein; Klaus Busam; Julie Teruya-Feldstein; Dana Sachs; Owen A O'Connor
Journal:  Br J Haematol       Date:  2006-08       Impact factor: 6.998

5.  Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.

Authors:  Chang-Ki Min; Seok Lee; Yoo-Jin Kim; Ki-Seong Eom; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim; Chul-Soo Cho; Gyeongsin Park
Journal:  Eur J Haematol       Date:  2006-03       Impact factor: 2.997

6.  Bortezomib-induced skin eruption.

Authors:  S Sanchez-Politta; L Favet; K Kerl; P-Y Dietrich; V Piguet
Journal:  Dermatology       Date:  2008-01-23       Impact factor: 5.366

7.  Innovative strategies in lymphoma therapy.

Authors:  Ulrich Jäger
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

Review 8.  Therapy strategies for multiple myeloma: current status.

Authors:  Heinz Gisslinger; Mathias Kees
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

9.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Authors:  Teru Hideshima; Constantine Mitsiades; Masaharu Akiyama; Toshiaki Hayashi; Dharminder Chauhan; Paul Richardson; Robert Schlossman; Klaus Podar; Nikhil C Munshi; Nicholas Mitsiades; Kenneth C Anderson
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.